JACOBSON PHARMA (02633) · Company profile · Eqvero

JACOBSON PHARMA

02633HKEX

Unit: HKD	FY2026	FY2025	FY2024	FY2023	FY2022
Revenue	1.57 bn HKD	1.58 bn HKD	1.47 bn HKD	1.79 bn HKD	1.6 bn HKD
Cost of revenue	738.92 m HKD	740.09 m HKD	705.5 m HKD	854.9 m HKD	783.37 m HKD
Research and development expense	1.15 m HKD	3.22 m HKD	7.85 m HKD	2.12 m HKD	7.59 m HKD
Selling, general and administrative expense	324.72 m HKD	324.24 m HKD	332.38 m HKD	428.07 m HKD	397.63 m HKD
Operating profit after depreciation	387.75 m HKD	434.45 m HKD	311.4 m HKD	350.08 m HKD	248.47 m HKD
Operating profit before depreciation	540.38 m HKD	578.32 m HKD	453.23 m HKD	533.59 m HKD	440.12 m HKD
EBIT	387.75 m HKD	434.45 m HKD	311.4 m HKD	350.08 m HKD	248.47 m HKD
EBITDA	540.38 m HKD	578.32 m HKD	453.23 m HKD	533.59 m HKD	440.12 m HKD
Interest expense	30.71 m HKD	41.37 m HKD	78.71 m HKD	67.45 m HKD	25.69 m HKD
Profit before tax	362.63 m HKD	373.63 m HKD	254.58 m HKD	339.76 m HKD	231.43 m HKD
Income tax expense	61.01 m HKD	72.79 m HKD	44.41 m HKD	56.55 m HKD	43.73 m HKD
Income before extraordinary items	301.62 m HKD	300.83 m HKD	186.36 m HKD	251.04 m HKD	177.67 m HKD
Common dividends	179.97 m HKD	179.81 m HKD	108.09 m HKD	99.06 m HKD	74.83 m HKD
Total dividends	179.97 m HKD	179.81 m HKD	108.09 m HKD	99.06 m HKD	74.83 m HKD

Quotes are end-of-day data. Content is for research purposes and is not investment advice.